世界のオリゴヌクレオチドベース治療法市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Oligonucleotide-based Therapies Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z4250 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、90ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、オリゴヌクレオチドベース治療法のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（アンチセンスオリゴヌクレオチド、アプタマー、その他）、用途別市場規模（神経筋疾患、肝静脈閉塞症、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・オリゴヌクレオチドベース治療法の市場動向 ・企業の競争状況、市場シェア ・オリゴヌクレオチドベース治療法の種類別市場規模（アンチセンスオリゴヌクレオチド、アプタマー、その他） ・オリゴヌクレオチドベース治療法の用途別市場規模（神経筋疾患、肝静脈閉塞症、その他） ・オリゴヌクレオチドベース治療法の北米市場規模2016-2027（アメリカ、カナダ） ・オリゴヌクレオチドベース治療法のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・オリゴヌクレオチドベース治療法のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・オリゴヌクレオチドベース治療法の中南米市場規模2016-2027（メキシコ、ブラジル） ・オリゴヌクレオチドベース治療法の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Biogen、Sarepta Therapeutics、Jazz Pharmaceuticals、Bausch & Lomb、Alnylam Pharmaceuticals、Dynavax Technologies、Kastle therapeutics、Akcea Therapeutics） ・結論

Market Analysis and Insights: Global Oligonucleotide-based Therapies Market
The global Oligonucleotide-based Therapies market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Oligonucleotide-based Therapies market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Oligonucleotide-based Therapies market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Oligonucleotide-based Therapies market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Oligonucleotide-based Therapies market.

Global Oligonucleotide-based Therapies Scope and Market Size
Oligonucleotide-based Therapies market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Oligonucleotide-based Therapies market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Antisense Oligonucleotide
Aptamer
Other

Segment by Application
Neuromuscular Diseases
Hepatic VOD
Other

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Biogen
Sarepta Therapeutics
Jazz Pharmaceuticals
Bausch & Lomb
Alnylam Pharmaceuticals
Dynavax Technologies

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oligonucleotide-based Therapies Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Antisense Oligonucleotide
1.2.3 Aptamer
1.2.4 Other
1.3 Market by Application
1.3.1 Global Oligonucleotide-based Therapies Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Neuromuscular Diseases
1.3.3 Hepatic VOD
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Oligonucleotide-based Therapies Market Perspective (2016-2027)
2.2 Oligonucleotide-based Therapies Growth Trends by Regions
2.2.1 Oligonucleotide-based Therapies Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Oligonucleotide-based Therapies Historic Market Share by Regions (2016-2021)
2.2.3 Oligonucleotide-based Therapies Forecasted Market Size by Regions (2022-2027)
2.3 Oligonucleotide-based Therapies Industry Dynamic
2.3.1 Oligonucleotide-based Therapies Market Trends
2.3.2 Oligonucleotide-based Therapies Market Drivers
2.3.3 Oligonucleotide-based Therapies Market Challenges
2.3.4 Oligonucleotide-based Therapies Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Oligonucleotide-based Therapies Players by Revenue
3.1.1 Global Top Oligonucleotide-based Therapies Players by Revenue (2016-2021)
3.1.2 Global Oligonucleotide-based Therapies Revenue Market Share by Players (2016-2021)
3.2 Global Oligonucleotide-based Therapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Oligonucleotide-based Therapies Revenue
3.4 Global Oligonucleotide-based Therapies Market Concentration Ratio
3.4.1 Global Oligonucleotide-based Therapies Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oligonucleotide-based Therapies Revenue in 2020
3.5 Oligonucleotide-based Therapies Key Players Head office and Area Served
3.6 Key Players Oligonucleotide-based Therapies Product Solution and Service
3.7 Date of Enter into Oligonucleotide-based Therapies Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Oligonucleotide-based Therapies Breakdown Data by Type
4.1 Global Oligonucleotide-based Therapies Historic Market Size by Type (2016-2021)
4.2 Global Oligonucleotide-based Therapies Forecasted Market Size by Type (2022-2027)

5 Oligonucleotide-based Therapies Breakdown Data by Application
5.1 Global Oligonucleotide-based Therapies Historic Market Size by Application (2016-2021)
5.2 Global Oligonucleotide-based Therapies Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Oligonucleotide-based Therapies Market Size (2016-2027)
6.2 North America Oligonucleotide-based Therapies Market Size by Type
6.2.1 North America Oligonucleotide-based Therapies Market Size by Type (2016-2021)
6.2.2 North America Oligonucleotide-based Therapies Market Size by Type (2022-2027)
6.2.3 North America Oligonucleotide-based Therapies Market Size by Type (2016-2027)
6.3 North America Oligonucleotide-based Therapies Market Size by Application
6.3.1 North America Oligonucleotide-based Therapies Market Size by Application (2016-2021)
6.3.2 North America Oligonucleotide-based Therapies Market Size by Application (2022-2027)
6.3.3 North America Oligonucleotide-based Therapies Market Size by Application (2016-2027)
6.4 North America Oligonucleotide-based Therapies Market Size by Country
6.4.1 North America Oligonucleotide-based Therapies Market Size by Country (2016-2021)
6.4.2 North America Oligonucleotide-based Therapies Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Oligonucleotide-based Therapies Market Size (2016-2027)
7.2 Europe Oligonucleotide-based Therapies Market Size by Type
7.2.1 Europe Oligonucleotide-based Therapies Market Size by Type (2016-2021)
7.2.2 Europe Oligonucleotide-based Therapies Market Size by Type (2022-2027)
7.2.3 Europe Oligonucleotide-based Therapies Market Size by Type (2016-2027)
7.3 Europe Oligonucleotide-based Therapies Market Size by Application
7.3.1 Europe Oligonucleotide-based Therapies Market Size by Application (2016-2021)
7.3.2 Europe Oligonucleotide-based Therapies Market Size by Application (2022-2027)
7.3.3 Europe Oligonucleotide-based Therapies Market Size by Application (2016-2027)
7.4 Europe Oligonucleotide-based Therapies Market Size by Country
7.4.1 Europe Oligonucleotide-based Therapies Market Size by Country (2016-2021)
7.4.2 Europe Oligonucleotide-based Therapies Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Oligonucleotide-based Therapies Market Size (2016-2027)
8.2 Asia-Pacific Oligonucleotide-based Therapies Market Size by Type
8.2.1 Asia-Pacific Oligonucleotide-based Therapies Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Oligonucleotide-based Therapies Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Oligonucleotide-based Therapies Market Size by Type (2016-2027)
8.3 Asia-Pacific Oligonucleotide-based Therapies Market Size by Application
8.3.1 Asia-Pacific Oligonucleotide-based Therapies Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Oligonucleotide-based Therapies Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Oligonucleotide-based Therapies Market Size by Application (2016-2027)
8.4 Asia-Pacific Oligonucleotide-based Therapies Market Size by Region
8.4.1 Asia-Pacific Oligonucleotide-based Therapies Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Oligonucleotide-based Therapies Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Oligonucleotide-based Therapies Market Size (2016-2027)
9.2 Latin America Oligonucleotide-based Therapies Market Size by Type
9.2.1 Latin America Oligonucleotide-based Therapies Market Size by Type (2016-2021)
9.2.2 Latin America Oligonucleotide-based Therapies Market Size by Type (2022-2027)
9.2.3 Latin America Oligonucleotide-based Therapies Market Size by Type (2016-2027)
9.3 Latin America Oligonucleotide-based Therapies Market Size by Application
9.3.1 Latin America Oligonucleotide-based Therapies Market Size by Application (2016-2021)
9.3.2 Latin America Oligonucleotide-based Therapies Market Size by Application (2022-2027)
9.3.3 Latin America Oligonucleotide-based Therapies Market Size by Application (2016-2027)
9.4 Latin America Oligonucleotide-based Therapies Market Size by Country
9.4.1 Latin America Oligonucleotide-based Therapies Market Size by Country (2016-2021)
9.4.2 Latin America Oligonucleotide-based Therapies Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Oligonucleotide-based Therapies Market Size (2016-2027)
10.2 Middle East & Africa Oligonucleotide-based Therapies Market Size by Type
10.2.1 Middle East & Africa Oligonucleotide-based Therapies Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Oligonucleotide-based Therapies Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Oligonucleotide-based Therapies Market Size by Type (2016-2027)
10.3 Middle East & Africa Oligonucleotide-based Therapies Market Size by Application
10.3.1 Middle East & Africa Oligonucleotide-based Therapies Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Oligonucleotide-based Therapies Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Oligonucleotide-based Therapies Market Size by Application (2016-2027)
10.4 Middle East & Africa Oligonucleotide-based Therapies Market Size by Country
10.4.1 Middle East & Africa Oligonucleotide-based Therapies Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Oligonucleotide-based Therapies Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Biogen
11.1.1 Biogen Company Details
11.1.2 Biogen Business Overview
11.1.3 Biogen Oligonucleotide-based Therapies Introduction
11.1.4 Biogen Revenue in Oligonucleotide-based Therapies Business (2016-2021)
11.1.5 Biogen Recent Development
11.2 Sarepta Therapeutics
11.2.1 Sarepta Therapeutics Company Details
11.2.2 Sarepta Therapeutics Business Overview
11.2.3 Sarepta Therapeutics Oligonucleotide-based Therapies Introduction
11.2.4 Sarepta Therapeutics Revenue in Oligonucleotide-based Therapies Business (2016-2021)
11.2.5 Sarepta Therapeutics Recent Development
11.3 Jazz Pharmaceuticals
11.3.1 Jazz Pharmaceuticals Company Details
11.3.2 Jazz Pharmaceuticals Business Overview
11.3.3 Jazz Pharmaceuticals Oligonucleotide-based Therapies Introduction
11.3.4 Jazz Pharmaceuticals Revenue in Oligonucleotide-based Therapies Business (2016-2021)
11.3.5 Jazz Pharmaceuticals Recent Development
11.4 Bausch & Lomb
11.4.1 Bausch & Lomb Company Details
11.4.2 Bausch & Lomb Business Overview
11.4.3 Bausch & Lomb Oligonucleotide-based Therapies Introduction
11.4.4 Bausch & Lomb Revenue in Oligonucleotide-based Therapies Business (2016-2021)
11.4.5 Bausch & Lomb Recent Development
11.5 Alnylam Pharmaceuticals
11.5.1 Alnylam Pharmaceuticals Company Details
11.5.2 Alnylam Pharmaceuticals Business Overview
11.5.3 Alnylam Pharmaceuticals Oligonucleotide-based Therapies Introduction
11.5.4 Alnylam Pharmaceuticals Revenue in Oligonucleotide-based Therapies Business (2016-2021)
11.5.5 Alnylam Pharmaceuticals Recent Development
11.6 Dynavax Technologies
11.6.1 Dynavax Technologies Company Details
11.6.2 Dynavax Technologies Business Overview
11.6.3 Dynavax Technologies Oligonucleotide-based Therapies Introduction
11.6.4 Dynavax Technologies Revenue in Oligonucleotide-based Therapies Business (2016-2021)
11.6.5 Dynavax Technologies Recent Development
11.7 Kastle therapeutics
11.7.1 Kastle therapeutics Company Details
11.7.2 Kastle therapeutics Business Overview
11.7.3 Kastle therapeutics Oligonucleotide-based Therapies Introduction
11.7.4 Kastle therapeutics Revenue in Oligonucleotide-based Therapies Business (2016-2021)
11.7.5 Kastle therapeutics Recent Development
11.8 Akcea Therapeutics
11.8.1 Akcea Therapeutics Company Details
11.8.2 Akcea Therapeutics Business Overview
11.8.3 Akcea Therapeutics Oligonucleotide-based Therapies Introduction
11.8.4 Akcea Therapeutics Revenue in Oligonucleotide-based Therapies Business (2016-2021)
11.8.5 Akcea Therapeutics Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Oligonucleotide-based Therapies Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Antisense Oligonucleotide
Table 3. Key Players of Aptamer
Table 4. Key Players of Other
Table 5. Global Oligonucleotide-based Therapies Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Oligonucleotide-based Therapies Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Oligonucleotide-based Therapies Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Oligonucleotide-based Therapies Market Share by Regions (2016-2021)
Table 9. Global Oligonucleotide-based Therapies Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Oligonucleotide-based Therapies Market Share by Regions (2022-2027)
Table 11. Oligonucleotide-based Therapies Market Trends
Table 12. Oligonucleotide-based Therapies Market Drivers
Table 13. Oligonucleotide-based Therapies Market Challenges
Table 14. Oligonucleotide-based Therapies Market Restraints
Table 15. Global Oligonucleotide-based Therapies Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Oligonucleotide-based Therapies Market Share by Players (2016-2021)
Table 17. Global Top Oligonucleotide-based Therapies Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Oligonucleotide-based Therapies as of 2020)
Table 18. Ranking of Global Top Oligonucleotide-based Therapies Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Oligonucleotide-based Therapies Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Oligonucleotide-based Therapies Product Solution and Service
Table 22. Date of Enter into Oligonucleotide-based Therapies Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Oligonucleotide-based Therapies Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Oligonucleotide-based Therapies Revenue Market Share by Type (2016-2021)
Table 26. Global Oligonucleotide-based Therapies Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Oligonucleotide-based Therapies Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Oligonucleotide-based Therapies Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Oligonucleotide-based Therapies Revenue Market Share by Application (2016-2021)
Table 30. Global Oligonucleotide-based Therapies Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Oligonucleotide-based Therapies Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Oligonucleotide-based Therapies Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Oligonucleotide-based Therapies Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Oligonucleotide-based Therapies Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Oligonucleotide-based Therapies Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Oligonucleotide-based Therapies Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Oligonucleotide-based Therapies Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Oligonucleotide-based Therapies Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Oligonucleotide-based Therapies Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Oligonucleotide-based Therapies Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Oligonucleotide-based Therapies Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Oligonucleotide-based Therapies Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Oligonucleotide-based Therapies Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Oligonucleotide-based Therapies Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Oligonucleotide-based Therapies Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Oligonucleotide-based Therapies Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Oligonucleotide-based Therapies Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Oligonucleotide-based Therapies Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Oligonucleotide-based Therapies Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Oligonucleotide-based Therapies Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Oligonucleotide-based Therapies Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Oligonucleotide-based Therapies Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Oligonucleotide-based Therapies Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Oligonucleotide-based Therapies Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Oligonucleotide-based Therapies Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Oligonucleotide-based Therapies Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Oligonucleotide-based Therapies Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Oligonucleotide-based Therapies Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Oligonucleotide-based Therapies Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Oligonucleotide-based Therapies Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Oligonucleotide-based Therapies Market Size by Country (2022-2027) & (US$ Million)
Table 62. Biogen Company Details
Table 63. Biogen Business Overview
Table 64. Biogen Oligonucleotide-based Therapies Product
Table 65. Biogen Revenue in Oligonucleotide-based Therapies Business (2016-2021) & (US$ Million)
Table 66. Biogen Recent Development
Table 67. Sarepta Therapeutics Company Details
Table 68. Sarepta Therapeutics Business Overview
Table 69. Sarepta Therapeutics Oligonucleotide-based Therapies Product
Table 70. Sarepta Therapeutics Revenue in Oligonucleotide-based Therapies Business (2016-2021) & (US$ Million)
Table 71. Sarepta Therapeutics Recent Development
Table 72. Jazz Pharmaceuticals Company Details
Table 73. Jazz Pharmaceuticals Business Overview
Table 74. Jazz Pharmaceuticals Oligonucleotide-based Therapies Product
Table 75. Jazz Pharmaceuticals Revenue in Oligonucleotide-based Therapies Business (2016-2021) & (US$ Million)
Table 76. Jazz Pharmaceuticals Recent Development
Table 77. Bausch & Lomb Company Details
Table 78. Bausch & Lomb Business Overview
Table 79. Bausch & Lomb Oligonucleotide-based Therapies Product
Table 80. Bausch & Lomb Revenue in Oligonucleotide-based Therapies Business (2016-2021) & (US$ Million)
Table 81. Bausch & Lomb Recent Development
Table 82. Alnylam Pharmaceuticals Company Details
Table 83. Alnylam Pharmaceuticals Business Overview
Table 84. Alnylam Pharmaceuticals Oligonucleotide-based Therapies Product
Table 85. Alnylam Pharmaceuticals Revenue in Oligonucleotide-based Therapies Business (2016-2021) & (US$ Million)
Table 86. Alnylam Pharmaceuticals Recent Development
Table 87. Dynavax Technologies Company Details
Table 88. Dynavax Technologies Business Overview
Table 89. Dynavax Technologies Oligonucleotide-based Therapies Product
Table 90. Dynavax Technologies Revenue in Oligonucleotide-based Therapies Business (2016-2021) & (US$ Million)
Table 91. Dynavax Technologies Recent Development
Table 92. Kastle therapeutics Company Details
Table 93. Kastle therapeutics Business Overview
Table 94. Kastle therapeutics Oligonucleotide-based Therapies Product
Table 95. Kastle therapeutics Revenue in Oligonucleotide-based Therapies Business (2016-2021) & (US$ Million)
Table 96. Kastle therapeutics Recent Development
Table 97. Akcea Therapeutics Company Details
Table 98. Akcea Therapeutics Business Overview
Table 99. Akcea Therapeutics Revenue in Oligonucleotide-based Therapies Business (2016-2021) & (US$ Million)
Table 100. Akcea Therapeutics Recent Development
Table 101. Research Programs/Design for This Report
Table 102. Key Data Information from Secondary Sources
Table 103. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Oligonucleotide-based Therapies Market Share by Type: 2020 VS 2027
Figure 2. Antisense Oligonucleotide Features
Figure 3. Aptamer Features
Figure 4. Other Features
Figure 5. Global Oligonucleotide-based Therapies Market Share by Application: 2020 VS 2027
Figure 6. Neuromuscular Diseases Case Studies
Figure 7. Hepatic VOD Case Studies
Figure 8. Other Case Studies
Figure 9. Oligonucleotide-based Therapies Report Years Considered
Figure 10. Global Oligonucleotide-based Therapies Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Oligonucleotide-based Therapies Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Oligonucleotide-based Therapies Market Share by Regions: 2020 VS 2027
Figure 13. Global Oligonucleotide-based Therapies Market Share by Regions (2022-2027)
Figure 14. Global Oligonucleotide-based Therapies Market Share by Players in 2020
Figure 15. Global Top Oligonucleotide-based Therapies Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Oligonucleotide-based Therapies as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Oligonucleotide-based Therapies Revenue in 2020
Figure 17. Global Oligonucleotide-based Therapies Revenue Market Share by Type (2016-2021)
Figure 18. Global Oligonucleotide-based Therapies Revenue Market Share by Type (2022-2027)
Figure 19. North America Oligonucleotide-based Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Oligonucleotide-based Therapies Market Share by Type (2016-2027)
Figure 21. North America Oligonucleotide-based Therapies Market Share by Application (2016-2027)
Figure 22. North America Oligonucleotide-based Therapies Market Share by Country (2016-2027)
Figure 23. United States Oligonucleotide-based Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Oligonucleotide-based Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Oligonucleotide-based Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Oligonucleotide-based Therapies Market Share by Type (2016-2027)
Figure 27. Europe Oligonucleotide-based Therapies Market Share by Application (2016-2027)
Figure 28. Europe Oligonucleotide-based Therapies Market Share by Country (2016-2027)
Figure 29. Germany Oligonucleotide-based Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Oligonucleotide-based Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Oligonucleotide-based Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Oligonucleotide-based Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Oligonucleotide-based Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Oligonucleotide-based Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Oligonucleotide-based Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Oligonucleotide-based Therapies Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Oligonucleotide-based Therapies Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Oligonucleotide-based Therapies Market Share by Region (2016-2027)
Figure 39. China Oligonucleotide-based Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Oligonucleotide-based Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Oligonucleotide-based Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Oligonucleotide-based Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Oligonucleotide-based Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Oligonucleotide-based Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Oligonucleotide-based Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Oligonucleotide-based Therapies Market Share by Type (2016-2027)
Figure 47. Latin America Oligonucleotide-based Therapies Market Share by Application (2016-2027)
Figure 48. Latin America Oligonucleotide-based Therapies Market Share by Country (2016-2027)
Figure 49. Mexico Oligonucleotide-based Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Oligonucleotide-based Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Oligonucleotide-based Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Oligonucleotide-based Therapies Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Oligonucleotide-based Therapies Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Oligonucleotide-based Therapies Market Share by Country (2016-2027)
Figure 55. Turkey Oligonucleotide-based Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Oligonucleotide-based Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Oligonucleotide-based Therapies Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Biogen Revenue Growth Rate in Oligonucleotide-based Therapies Business (2016-2021)
Figure 59. Sarepta Therapeutics Revenue Growth Rate in Oligonucleotide-based Therapies Business (2016-2021)
Figure 60. Jazz Pharmaceuticals Revenue Growth Rate in Oligonucleotide-based Therapies Business (2016-2021)
Figure 61. Bausch & Lomb Revenue Growth Rate in Oligonucleotide-based Therapies Business (2016-2021)
Figure 62. Alnylam Pharmaceuticals Revenue Growth Rate in Oligonucleotide-based Therapies Business (2016-2021)
Figure 63. Dynavax Technologies Revenue Growth Rate in Oligonucleotide-based Therapies Business (2016-2021)
Figure 64. Kastle therapeutics Revenue Growth Rate in Oligonucleotide-based Therapies Business (2016-2021)
Figure 65. Akcea Therapeutics Revenue Growth Rate in Oligonucleotide-based Therapies Business (2016-2021)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed

---